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Introduction
Candida is the most common human fungal pathogen and the
cause of invasive candidiasis, the fourth leading cause of
nosocomial bloodstream infection in the United States with an
estimated annual cost of,US$2 billion and mortality that exceeds
40% despite administration of antifungal therapy in modern
intensive care unit facilities [1]. Hence, invasive candidiasis is an
unmet medical condition for which better understanding of its
pathogenesis at the host–pathogen interface is essential to improve
patient outcomes. To that end, a mouse model of the infection,
which introduces Candida yeast cells intravenously and mimics
skin-derived bloodstream human candidiasis, has been successfully
employed to study fungal and host factors that regulate
susceptibility to the infection [2].
Which Candida Virulence Factors Influence the
Outcome of Invasive Candidiasis?
Candida expresses a variety of virulence factors that contribute to
its pathogenesis and could be exploited for development of
vaccines and targeted therapeutic strategies. Firstly, Candida
albicans filaments’ virulence factors, including secreted aspartyl
proteases and phospholipases, are thought to be important for
Candida invasion in infected organs and, probably, for mediating
fungus-induced tissue immunopathology [3]. Secondly, Candida is
able to efficiently adhere to and invade epithelial and endothelial
cells via induced endocytosis and active penetration; both adhesion
and invasion facilitate Candida dissemination [4]. Effective
adhesion also enables Candida to form biofilms on implanted
medical devices such as central venous catheters, which are a
frequent portal of entry for invasive infection in humans [5].
Among the known Candida factors that promote its adhesion and
invasion, the agglutinin-like sequence (Als) family has attracted
significant attention; Als3 in particular, a C. albicans–specific
virulence factor, was recently shown to mediate brain-specific
Candida endothelial invasion and tissue penetration [6]. Specifi-
cally, increased surface expression of Als3 in the vps51D/D C.
albicans mutant was shown to be responsible for its increased ability
to invade brain endothelial cells in vitro and traffic to the brain in
vivo via binding to the gp96 heat shock protein, which is expressed
specifically on brain endothelium [6]. Als3 has formed the basis for
the development of a cell wall protein-based vaccine strategy
against candidiasis, which was recently tested safely in humans in a
Phase I clinical trial [7]. Studies in mice revealed that IFN-c and
IL-17a produced by Th1 and Th17 lymphocytes were essential for
vaccine-induced protection, via Ccl3- and Cxcl1-mediated neu-
trophil recruitment to sites of infection, which resulted in
decreased Candida tissue burden [8].
Moreover, a fundamental C. albicans virulence factor is its ability
to transition between unicellular yeast cells and filamentous
growth during infection; in fact, it is the interchange between these
morphotypes that is critical for pathogenesis, as strains locked
either in the yeast or the filamentous forms have attenuated
virulence in vivo [9,10]. Of note, this morphogenic transition is
not a prerequisite for virulence in non-albicans Candida species such
as Candida glabrata, which is an important cause of invasive
candidiasis in humans even though it does not form hyphae.
Strikingly, the ability of C. albicans to form filaments in vivo is
tissue-specific [2]. Hence, organs that successfully inhibit Candida
growth in mice such as the liver and spleen prevent Candida
filamentation, whereas hyphal formation is abundant in the
kidney, the target organ of murine disseminated candidiasis, where
Candida proliferation is inexorable [2]. Therefore, identifying
tissue-specific immunological factors and environmental cues that
restrict Candida filamentation could lead to the discovery of novel
therapeutic interventions.
How Does the Innate Immune System Recognize
Candida?
The first step in mounting an effective anti-Candida immune
response is fungal recognition by the innate immune system. Over
the past decade there has been an explosion in our understanding
of how soluble and membrane-bound pattern recognition recep-
tors (PRRs) recognize various pathogen-associated molecular
patterns (PAMPs) of Candida yeast and filamentous forms (Text
S1) (reviewed in [11,12]). In brief, the complement components
C3 and C5, the complement receptor 3 (CR3), the Toll-like
receptors (TLR)-2 (in interaction with TLR1 and TLR6), TLR4,
TLR7, and TLR9, and the C-type lectins (CLRs) dectin-1, dectin-
2, mannose receptor, DC-SIGN, and Mincle are among the PRRs
shown to recognize different fungal PAMPs including mannan, b-
glucan, RNA, and DNA (Figure 1); several of these PRRs are
indispensable for host defense in vivo by inducing the secretion of
pro-inflammatory cytokines and chemokines and modulating
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innate and adaptive antifungal immune responses (Text S1)
[11,12]. In fact, synergistic interactions between different PRRs
resulting in augmented downstream immune activation have been
demonstrated, such as between TLRs and CLRs or C5a and
TLRs [11,12]. Candida also activates the inflammasome; both the
Nlrp3/caspase-1 pathway and the non-canonical caspase-8
pathway have been implicated in IL-1b production via dectin-1/
syk activation by b-glucans (Figure 1) [12,13].
The challenge for future research will be to define how Candida
recognition is integrated by the array of different PRRs in vivo
and to determine what is the relative contribution of individual
PRRs on different myeloid cells (e.g., dectin-1 or CR3 as b-
glucan receptors on neutrophils versus monocytes/macrophages
versus dendritic cells) in modulating downstream anti-Candida
immune responses. In addition, more studies are needed to
understand how Candida influences its recognition in vivo by
employing immune evasion strategies; for example, b-glucan
exposure on the Candida surface occurs in infected mouse tissues
only late after infection [14], thus preventing CLR-mediated
pathogen recognition during the early phase of invasive infection,
Figure 1. The principal cell surface pattern recognition receptors involved in Candida recognition. The Toll-like receptor 2 (TLR2) and
TLR4 recognize phospholipomannans and O-linked mannans, respectively, whereas TLR9 within the cytosol recognizes fungal DNA, and intracellular
TLR7 (not depicted) recognizes fungal RNA. TLR2 forms heterodimers with TLR1 or TLR6 for downstream signaling (not depicted), whereas TLR4 forms
homodimers. Galectin-3, together with TLR2, recognizes b-mannosides. The membrane-bound C-type lectins dendritic cell–specific ICAM3-grabbing
non-integrin (DC-SIGN), macrophage-inducible C-type lectin (Mincle), and macrophage mannose receptor (MR) recognize mannose-rich Candida
structures. In addition, dectin-1 recognizes b-glucans, and dectin 2, together with the Fcc receptor (FccR), recognizes mannans. The complement
receptor 3 (CR3) on neutrophils also recognizes b-glucans. Moreover, the NOD-like receptor NLRP3 (nucleotide-binding domain, leucine-rich-repeat-
containing family, pyrin domain-containing 3) forms an inflammasome complex with ASC (apoptosis-associated speck-like protein containing a
caspase recruitment domain) and caspase 1, which leads to interleukin-1b (IL-1b) production. In addition, downstream dectin-1 signaling through
caspase recruitment domain-containing protein 9 (CARD9) leads to non-canonical inflammasome activation and IL-1b production via caspase 8. IFNs,
interferons; NF-kB, nuclear factor-kB; Syk, spleen tyrosine kinase; IRF3, interferon regulatory factor 3; TRIF, TIR-domain-containing adapter-inducing
interferon-b; MyD88, myeloid differentiation primary response gene 88; BCL-10, B-cell lymphoma/leukemia 10; MALT1, mucosa-associated lymphoid
tissue lymphoma translocation protein 1; TRAF6, TNF receptor–associated factor 6; IRAK, interleukin-1 receptor-associated kinase.
doi:10.1371/journal.ppat.1003079.g001
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when recruitment of effector immune cells is critical for survival
[15].
In addition, the notable diversity in PAMP structure among
various Candida experimental strains impedes on drawing definite
conclusions about the in vivo role of certain PRRs, as apparently
discrepant results have been reported for some TLRs and CLRs
with different fungal strains [11,12,16]. To that end, the logistical
and economical constraints associated with testing large numbers
of Candida strains in mammals could potentially be ameliorated by
employing non-vertebrate (e.g., Drosophila melanogaster) and/or
mini-vertebrate model hosts (e.g., zebrafish) that have evolution-
arily conserved innate immune pathways (e.g., TLR signaling),
and could allow for facile and inexpensive high-throughput
screening of greater numbers of Candida strains [17]. Not
surprisingly, as C. albicans is the most common agent of human
invasive candidiasis, research performed until now has predom-
inantly focused on the recognition of this species, and much less is
known about the interaction of other Candida species with the
immune system. It is expected that research aiming to gain more
insight on the recognition of emerging non-albicans Candida species
will represent an important area of research in the coming years.
What Are the Divergent Roles of Neutrophils
during Invasive Candidiasis?
Neutrophils are indispensable for host defense against invasive
candidiasis, and neutropenia is a well-recognized risk factor for
development of and adverse outcome after infection in humans
[1]. The protective effects of neutrophils are mediated via
oxidative and non-oxidative mechanisms that result in efficient
Candida killing [12]. Specifically, Candida ingestion is followed by
assembly of the nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase complex at the phagosomal membrane and
oxidative burst, which leads to generation of candidacidal reactive
oxygen species and K+-influx–induced activation of neutrophil
candidacidal granular proteases [12]. Neutrophils are the only
effector cells able to inhibit Candida yeast-to-hyphae conversion, a
process dependent on the oxidative burst [12]. The oxidative burst
is also important for generation of neutrophil extracellular traps,
which ensnare Candida yeasts and hyphae and appear important
for anti-Candida host defense in vivo [18].
Nonetheless, neutrophils have differential effects in invasive
candidiasis in vivo depending on the phase of the infection in mice.
Specifically, early neutrophil presence after infection is protective,
whereas neutrophil presence late after infection is pathogenic [15].
The requirement of early neutrophil accumulation for effective
host defense appears to correlate with the organ-specific micro-
biological progression of invasive candidiasis [2]; thus, liver and
spleen, which recruit large numbers of neutrophils early post-
infection, effectively control fungal growth. Conversely, sluggish
early accumulation of neutrophils in the kidney is associated with
unabated fungal proliferation [2]. With regard to the pathogenic
role of neutrophils late after infection, we recently reported that
the chemokine receptor Ccr1 drives neutrophil-induced tissue
immunopathology and mortality in invasive candidiasis by
mediating neutrophil trafficking from the blood into the kidney
during the late phase of the infection [19]. In addition, late
neutrophil accumulation into the infected kidney was shown to
depend on type I interferon signaling, which mediated tissue
immunopathology and mortality [20]. Future research will be
required to define the role of regulatory T cells and anti-
inflammatory mediators including cytokines in restricting neutro-
phil-mediated tissue injury in invasive candidiasis. Of interest, in a
subset of patients with invasive candidiasis, neutrophils exhibit
pathogenic effects, as recovery from neutropenia is associated with
worsening symptoms that requires corticosteroid administration
[21]. Hence, identification of Ccr1, Ifnar1, and other molecular
factors that mediate pathogenic neutrophil effects in invasive
candidiasis could potentially lead to targeted therapeutic inter-
ventions in selected patients.
What Is the Role of Other Immune Cell Types in
Host Defense against Invasive Candidiasis?
Besides neutrophils, monocytes/macrophages are key phago-
cytic cells for protection against invasive candidiasis, as their
depletion in mice leads to increased mortality [22]. Monocytes/
macrophages are very effective in Candida phagocytosis and
secretion of a variety of pro-inflammatory cytokines and
chemokines that orchestrate the antifungal innate immune
response [12]. Nevertheless, macrophages are significantly less
able to inhibit yeast germination and kill Candida compared to
neutrophils; the lack of macrophage myeloperoxidase and
extracellular trap formation may, at least in part, account for this
deficit [12]. On the other hand, the concomitant release of
superoxide and nitric oxide, with the subsequent formation of
peroxinitrite, has been suggested to mediate the macrophage anti-
Candida effects in mice; yet, the importance of Candida-induced
nitric oxide formation in human phagocytes is unclear [12].
Several studies have demonstrated the priming role of Th1
cytokines and the inhibitory role of Th2 cytokines on the
macrophage killing capacity, but more research is required to
elucidate the molecular mechanisms of macrophage activation and
effector function in vivo at the sites of Candida infection. In
addition, future studies should aim to shed light on the relative role
of recruited versus resident monocytes/macrophages in host
defense against invasive candidiasis.
Intriguingly, besides the protective role of monocytes/macro-
phages in host defense against primary Candida challenge,
monocytes were recently shown to also confer protection following
systemic Candida re-infection via functional reprogramming that
involves the dectin-1/Raf-1 non-canonical signaling pathway and
results in enhanced cytokine production [23]. This monocyte/
macrophage reprogramming that results in innate immune
memory (termed ‘‘trained immunity’’) appears to involve epige-
netic mechanisms mediated via stable changes in histone
trimethylation at H3K4 [23]. Thus, induction of trained immunity
shows promise for the potential design of novel vaccination
strategies against candidiasis.
The role of other hematopoietic cells in host defense against
invasive candidiasis merits further investigation. For example,
dendritic cells are able to phagocytize Candida yeast and hyphal
forms and respond differentially to the Candida morphotypes by
priming the production of distinct cytokines [24]. In addition,
CD1d+ dendritic cells were recently shown to activate invariant
natural killer T cells to mediate innate immune responses against
fungi (including Candida) via dectin-1- and MyD88-dependent
mechanisms without apparent requirement for fungal lipid antigen
presentation [25]. However, the in vivo role of different dendritic
cell subsets remains unclear, partly owing to technical difficulties in
achieving specific dendritic cell depletion. Moreover, consistent
with the lack of enhanced susceptibility of patients with acquired
immunodeficiency syndrome, severe combined immunodeficien-
cy, X-linked agammaglobulinemia, and common variable immu-
nodeficiency to invasive candidiasis, T and B lymphocytes are
dispensable for host defense in the mouse model [26]. Nonetheless,
T lymphocytes play a critical role in protection against mucosal
candidiasis [26]. In addition, the recent demonstration of direct
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IgA-mediated anti-Candida effects after systemic infection [27] and
of protective Th17-mediated responses by Candida-specific CD4+
T cells after systemic infection of mice vaccinated with the Als-
derived peptide pALS [28] suggest that exploiting antibody-
mediated and cell-mediated anti-Candida immunity could lead to
the design of effective vaccination and immunomodulatory
strategies against invasive and mucosal candidiasis in patients.
What Host Factors Mediate Protection against
Invasive Candidiasis in Humans?
In agreement with the requirement of innate immunity for
effective host defense in the mouse model of invasive candidiasis,
certain innate immune factors have been associated with
protection against the infection in humans [26]. Consistent with
the crucial role of the NADPH oxidase in phagocyte killing and
the heightened susceptibility of NADPH oxidase-deficient mice to
invasive candidiasis [8,12], patients with chronic granulomatous
disease are at increased risk for development of the infection [26].
In addition, in line with the enhanced susceptibility of myeloper-
oxidase-deficient mice to invasive candidiasis and the impaired
anti-Candida killing capacity of human myeloperoxidase-deficient
phagocytes, invasive candidiasis occurs in patients with myeloper-
oxidase deficiency, the most common inherited phagocytic
disorder [26]. Yet, the majority of myeloperoxidase-deficient
patients are asymptomatic, and invasive candidiasis develops only
in patients with autosomal-recessive complete myeloperoxidase
deficiency who also have concomitant disorders that adversely
affect phagocyte function such as diabetes [26].
On the other hand, there is no universal concordance between
humans and mice in regard to the importance of fungal PRRs and
pro-inflammatory cytokines in host defense against invasive
candidiasis. Hence, complement deficiencies and MyD88 muta-
tions do not appear to confer a significant risk for invasive
candidiasis in humans as opposed to mice [26]; however, a recent
large cohort study demonstrated that TLR1 single nucleotide
polymorphisms in Caucasian patients were associated with
heightened risk for development of invasive candidiasis, suggesting
that TLR signaling may contribute to optimal anti-Candida
immunity in humans [29]. Furthermore, mutations in the adaptor
molecule CARD9 predispose to both invasive and chronic
mucocutaneous candidiasis (Text S1) [26], whereas dectin-1
mutations appear to be associated with chronic mucocutaneous
but not invasive candidiasis in humans; instead, Card92/2 and
dectin-12/2 mice are both susceptible to invasive candidiasis (Text
S1) [26] Finally, Johnson and colleagues recently examined the
impact of cytokine polymorphisms on host susceptibility to
invasive candidiasis and reported that polymorphisms in IL-10
and IL-12B, but not IL-1b or IFN-c, were associated with
persistent fungemia in patients with candidemia [30]. Future
studies will be required to identify additional genetic risk factors
for development of and/or adverse outcome after invasive
candidiasis, as such knowledge could eventually lead to individ-
ualized risk stratification and prognostication strategies for
patients.
Perspective
Candida is a commensal organism that colonizes 50% of
individuals of a population at any given time, but in conditions
leading to weakening of host defense mechanisms it can convert to
an opportunistic pathogen causing localized mucosal disease or
life-threatening invasive infections with high mortality rate despite
antifungal therapy. In recent years we have witnessed a surge of
studies of Candida pathogenesis at the host–pathogen interface.
Dissecting the fungal virulence factors that foster the transition of
Candida from a commensal to an opportunistic pathogen, and
deepening our understanding of the molecular and cellular basis of
effective antifungal immunity should lead to novel risk stratifica-
tion, prognostication, vaccination, and therapeutic strategies in
patients.
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